CD147 and cyclophilin A: a promising potential targeted therapy for COVID-19 and associated cancer progression and chemo-resistance.
Maryam BakhtiyariAyda Haji AghasiSara BanihashemiArian AbbassiounChanour TavakolHamidreza ZalpoorPublished in: Infectious agents and cancer (2023)
Coronavirus disease-2019 (COVID-19), as a worldwide serious issue has been shown to lead to progression and poor outcomes in cancer patients. The underlying mechanisms for SARS-CoV-2 infection's adverse effects on cancer patients have not been fully understood. We hypothesized that CD147 and Cyclophilin A (CyPA) not only can play a significant role in infection severity but also can contribute to cancer progression and chemotherapy resistance in cancer patients with COVID-19. In addition, we hypothesized that the expression of both CD147 and CyPA could be increased by Hypoxia-inducible Factor-1 alpha (HIF-1α) activation during hypoxic conditions that occurred during COVID-19. Therefore, this evidence can open a new window in the management of cancer patients during the pandemic and therapeutic approaches targeting CD147 and CyPA could be a potentially promising therapeutic approach for such patients.
Keyphrases
- coronavirus disease
- papillary thyroid
- sars cov
- squamous cell
- respiratory syndrome coronavirus
- cancer therapy
- end stage renal disease
- nk cells
- type diabetes
- childhood cancer
- weight loss
- peritoneal dialysis
- chronic kidney disease
- lymph node metastasis
- minimally invasive
- locally advanced
- endothelial cells
- glycemic control
- prognostic factors
- insulin resistance
- combination therapy